Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials

Ophthalmology

Volumn 123, Issue 8, 2016, Pages 1751-1761

  Maguire, Maureen G ^a   Martin, Daniel F ^b   Ying, Gui shuang ^a   Jaffe, Glenn J ^c   Daniel, Ebenezer ^a   Grunwald, Juan E ^a   Toth, Cynthia A ^c   Ferris, Frederick L ^d   Fine, Stuart L ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTERY THROMBOSIS; COHORT ANALYSIS; CONFERENCE PAPER; DRUG FATALITY; FEMALE; FOLLOW UP; GEOGRAPHIC ATROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINAL PIGMENT EPITHELIUM; RETINAL THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA; SUBRETINAL FLUID; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COHORT STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GEOGRAPHIC ATROPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINA; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84964865566     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.03.045     Document Type: Conference Paper

References (40)

1. 1 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
2. 2 Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1432–1444.
3. 3 Rosenfeld, P.J., Moshfeghi, A.A., Puliafito, C.A., Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005), 331–335.
4. 4 Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006), 363–372.
5. 5 Curtis, L.H., Hammill, B.G., Schulman, K.A., Cousins, S.W., Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128 (2010), 1273–1279.
6. 6 The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364 (2011), 1897–1908.
7. 7 The CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology 119 (2012), 1388–1398.
8. 8 The IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One-year findings from the IVAN randomized trial. Ophthalmology 119 (2012), 1399–1411.
9. 9 Chakravarthy, U., Harding, S.P., Rogers, C.A., et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382 (2013), 1258–1267.
10. 10 Kodjikian, L., Souied, E.H., Mimoun, G., et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 120 (2013), 2300–2309.
11. 11 Krebs, I., Schmetterer, L., Boltz, A., et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97 (2013), 266–271.
12. 12 Berg, K., Pederson, T.R., Sandvik, L., Bragadottir, R., Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122 (2015), 146–152.
13. 13 Berg, K., Hadzalic, E., Gjertsen, I., et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results. Ophthalmology 123 (2016), 51–59.
14. 14 Schauwvlieghe, A.-S.M., Dijkman, G., Hooymans, J.M., et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. BRAMD. Invest Ophthalmol Vis Sci, 55, 2014 ARVO E-Abstract 870.
15. 15 Solomon, S.D., Lindsley, K.B., Krzystolik, M.G., et al. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane Systematic Review. Ophthalmology 123 (2016), 70–77.
16. 16 Heier, J.S., Brown, D.M., Chong, V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
17. 17 Schmidt-Erfurth, U., Kaiser, P.K., Korobelnik, J.F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121 (2014), 193–201.
18. 18 Arevalo, J.F., Lasave, A.F., Wu, L., et al. Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 36 (2016), 859–867.
19. 19 Singer, M.A., Awh, C.C., Sadda, S., et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119 (2012), 1175–1183.
20. 20 Gillies, M.C., Campain, A., Barthelmes, D., et al. Long-term outcomes of treatment of neovascular age-related macular degeneration. Ophthalmology 122 (2015), 1837–1845.
21. 21 Peden, M.C., Suner, I.J., Hammer, M.E., et al. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 122 (2015), 803–808.
22. 22 Rasmussen, A., Bloch, S.B., Fuchs, S., et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 120 (2013), 2630–2636.
23. 23 Rofagha, S., Bhisitkul, R.B., Boyer, D.S., et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON. A multicenter cohort study (SEVEN-UP). Ophthalmology 120 (2013), 2292–2299.
24. 24 Zhu, M., Chew, J.K., Broadhead, G.K., et al. Intravitreal ranibizumab for neovascular age-related macular degeneration in clinical practice: five-year treatment outcomes. Graefes Arch Clin Exp Ophthalmol 253 (2015), 1217–1225.
25. 25 Grunwald, J.E., Daniel, E., Ying, G.-S., et al., the CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 119 (2012), 1634–1641.
26. 26 DeCroos, F.C., Toth, C.A., Stinnett, S.S., et al., for the CATT Research Group. Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 119 (2012), 2549–2557.
27. 27 Chan, A., Duker, J.S., Ko, T.H., et al. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 124 (2006), 193–198.
28. 28 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994), 81–106.
29. 29 Chen, H.X., Cleck, J.N., Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6 (2009), 465–477.
30. 30 Nalluri, S.R., Chu, D., Keresztes, R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300 (2008), 2277–2285.
31. 31 Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 111 (1993), 1200–1209.
32. 32 Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report #2. Arch Ophthalmol 119 (2001), 198–207.
33. 33 Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 131 (2001), 541–560.
34. 34 Brown, D.M., Michels, M., Kaiser, P.K., et al., ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology 116 (2009), 57–65.
35. 35 Elman, M.J., Ayala, A., Bressler, N.M., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122 (2015), 375–381.
36. 36 Jaffe, G.J., Martin, D.F., Toth, C.A., et al. Macular morphology and visual acuity in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 120 (2013), 1860–1870.
37. 37 Sharma, S., Toth, C.A., Daniel, E., et al. Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123 (2016), 865–875.
38. 38 Schmidt-Erfurth, U., Waldstein, S.M., Deak, G.-G., et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in the treatment of neovascular age-related macular degeneration. Ophthalmology 122 (2015), 822–832.
39. 39 Holz, F.G., Tuomi, L., Ding, B., Hopkins, J.J., Development of atrophy in neovascular AMD treated with ranibizumab in the HARBOR study. Invest Ophthalmol Vis Sci, 56, 2015 ARVO E-Abstract 890.
40. 40 Moja, L., Lucenteforte, E., Kwag, K., et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev, 9, 2014, CD011230.